LOS ANGELES--(BUSINESS WIRE)--April 4, 2006--CytRx Corporation (NASDAQ:CYTR - News), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced the successful completion of enrollment of 84 patients in the first clinical trial with its lead small molecule product candidate arimoclomol for the treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). CytRx expects to report final data from this Phase IIa trial in the third quarter of this year, followed by initiation of a Phase IIb efficacy trial, subject to approval from the U.S. Food and Drug Administration (FDA).
